Update on second primary malignancies in multiple myeloma: a focused review (Q38178031)

30 August 2017

title

Update on second primary malignancies in multiple myeloma: a focused review (English)

1 reference

30 August 2017

1 reference

O Landgren

1 reference

30 August 2017

S Mailankody

series ordinal

1 reference

30 August 2017

publication date

14 January 2014

1 reference

30 August 2017

1 reference

30 August 2017

1 reference

30 August 2017

1 reference

30 August 2017

page(s)

1423-1426

1 reference

Lenalidomide after stem-cell transplantation for multiple myeloma

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

Second malignancies after multiple myeloma: from 1960s to 2010s

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

Multiple myeloma and acute myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

MELPHALAN THERAPY IN MYELOMATOSIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

Chromosomal localization and cDNA cloning of the genes (DDB1 and DDB2) for the p127 and p48 subunits of a human damage-specific DNA binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.22

Improved long-term survival in multiple myeloma up to the age of 80 years

21 January 2018

1 reference

12 December 2020

High-dose intravenous melphalan for plasma-cell leukaemia and myeloma

1 reference

12 December 2020

MULTIPLE MYELOMA I. THE PATHOGENESIS OF "AMYLOIDOSIS

1 reference

12 December 2020

1 reference

12 December 2020

Myeloma and second primary cancers

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2014.22

1 reference

Dimensions Publication ID

30 August 2017

1019841777

0 references

1 reference